Amgen Raises The Oncology Drug Price Bar With Blincyto
This article was originally published in The Pink Sheet Daily
The first-in-class bispecific T-cell engager (BiTE) antibody will cost $178,000 for a median treatment regimen of two cycles, the company announced.
You may also be interested in...
Priced at $12,500/month, Keytruda will be ready to ship within one week of FDA approval for relapsed melanoma after failure of Yervoy and a BRAF inhibitor. Approval could spur interest in off-label use of PD-1 inhibitor as a first-line treatment.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.